Media Details

  • Home
  • Media
  • Details
  2020-09-18 20:53:47

Ho Wah Genting Berhad’s joint venture with EBI will conduct COVID-19 clinical research study upon receiving FDA approval and in accordance with FDA approved protocol

KUALA LUMPUR, 18 SEPTEMBER 2020 – Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code:9601) today announced its wholly owned subsidiary HWGB Biotech Sdn Bhd’s (“HWGB Biotech”) [formerly known as HWG Consortium Sdn Bhd] joint venture partner, US-based E-MO Biology Inc. (“EBI”), had entered into three agreements for R&D together with supporting investigative procedures leading to a COVID-19 vaccine, as follows:
1.     E-MO Biology Inc (EBI) contracted Dr. John Andrews through Black Diamond Networks (Professional service agreement) to support US FDA IND application project based upon his 25 years direct experiences in regard to vaccine development & clinical phase IV study.
2.     E-MO Biology Inc (EBI) to engaged  the services of Roderick A. Comunale II MD Inc to conduct a clinical research study entitled “Inactivated Polio Vaccine in prevention of COVID-19 in high risk population in a Phase IV study", which shall study the effects of Inactivate Polio Vaccine-IPV which shall be conducted according to the United States Food and Drug Administration approved protocol and to be provided by EBI.
3.     E-MO Biology Inc (EBI) collaboration with America Diagnostic & Genescan Diagnostics Inc
 i.        E-MO Biology Inc (EBI) engage the biomedical assay development services of America Diagnostic & Genescan Diagnostics Inc to conduct a series of immunology assays in supporting the potential clinic research entitled "Inactivated Polio Vaccine in prevention of COVID-19 in Patients with general population in a Phase IV Research and Development."
ii.        E-MO Biology Inc (EBI) to collaborate with America Diagnostic & Genescan Diagnostics Inc as a strategic partner involved with research, development and production of the companion diagnostics systems.
Chief Executive Officer of HWGB, Dato’ Aaron Lim said: “The agreements facilitating the R&D including the clinical trials for a COVID-19 vaccine are crucial to the clinical trials. These agreements bring in the needed expertise that will help boost the clinical trials that must be conducted in accordance with US laws”.
“We look forward to the fruitful work that will come from the collaborations with our partners and we again want to emphasise that time is important in the production of the vaccine given how the pandemic has ravaged through Southeast Asia’s population and weigh on its economy,” Dato Aaron Lim added.
Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in Health Supplement, Biotechnology and Health Technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of Investment holdings; manufacturing of wire and cable and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; trading of wire and cable; and travel agent and tour related services.
For more information about HWGB Biotech, please visit and/or Please also feel free to subscribe to our newsletter online to get latest exciting developments of our new ventures. Click on to subscribe.
Emo-Biology Inc (“EBI”) was incorporated in the state of California in the United States of America on 24 May 2020. It is principally involved in conducting biology research and development activities and is the sponsor of a study which indicates booster polio vaccine to reduce Covid-19 SARS-COV-2 infection and severity.
EBI is founded by Xie QiYi, who serves as its Managing Director of EBI. He has over 30 years of experiences in areas of public health and infection disease control. He was also involved in the development of medical and diagnostic devices, with focus on Quality, Regulatory and Clinical Affairs for quality systems.